KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Retained Earnings (2021 - 2025)

Recursion Pharmaceuticals' Retained Earnings history spans 5 years, with the latest figure at -$2.1 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 27397.71% year-over-year to -$2.1 billion; the TTM value through Dec 2025 reached -$2.1 billion, down 27397.71%, while the annual FY2025 figure was -$2.1 billion, 27397.71% down from the prior year.
  • Retained Earnings reached -$2.1 billion in Q4 2025 per RXRX's latest filing, down from -$2.0 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $14.1 million in Q1 2025 to a low of -$2.1 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$737.6 million, with a median of -$672.2 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 507484.13% in 2022, then surged 101.34% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$126000.0 in 2021, then tumbled by 507484.13% to -$639.6 million in 2022, then crashed by 36.76% to -$874.6 million in 2023, then surged by 99.13% to -$7.6 million in 2024, then plummeted by 27397.71% to -$2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Retained Earnings are -$2.1 billion (Q4 2025), -$2.0 billion (Q3 2025), and -$1.8 billion (Q2 2025).